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Context:  There are no approved therapies for the treatment of metastatic and/or recurrent 
pheochromocytoma or paraganglioma (PPGL) in the United States.   
Objective:  To determine the maximum tolerated dose (MTD) of high-specific-activity I-131 
meta-iodobenzylguanidine (MIBG) for the treatment of metastatic and/or recurrent PPGL.   
Design: Phase 1, dose escalating study to determine the MTD via a standard 3+3 design; 
escalating by 37 MBq/kg starting at 222 MBq/kg. 
Setting: Three centers. 
Patients:  Twenty-one patients were eligible, received study drug, and were evaluable for MTD, 
response, and toxicity.  
Intervention:  Open-label use of high-specific-activity I-131 MIBG therapy. 
Main Outcome Measures:  Dose-limiting toxicities, adverse events, radiation absorbed dose 
estimates, radiographic tumor response, biochemical response, and survival. 
Results:  The MTD was determined to be 296 MBq/kg based on two observed dose-limiting 
toxicities at the next dose level.  The highest mean radiation absorbed dose estimates were in the 
thyroid and lower large intestinal wall (each 1.2 mGy/MBq).  Response was evaluated by total 
administered activity: four (19%) patients, all of whom received >18.5 GBq of study drug, had 
radiographic tumor responses of partial response by RECIST.  Best biochemical responses 
(complete or partial response) for serum chromogranin A and total metanephrines were observed 
in 80% and 64% of patients, respectively.  Overall survival was 85.7% at 1 year and 61.9% at 2 
years post-treatment.  The majority (84%) of adverse vents were considered mild or moderate in 
severity. 
Conclusions:  These findings support further development of high-specific-activity I-131 MIBG 
for the treatment of metastatic and/or recurrent PPGL at a MTD of 296 MBq/kg. 
We studied the maximum tolerated dose (MTD) and preliminary efficacy of high-specific-activity I-131 
MIBG therapy in patients with metastatic and/or recurrent PPGL, and found the MTD to be 296 MBq/kg. 
Introduction 
Pheochromocytomas and paragangliomas (PPGL) are rare neuroendocrine tumors arising from 
adrenal medullary chromaffin cells or extra-adrenal sympathetic neurons, respectively.  
Paraganglioma can also arise from parasympathetic nuro s, largely in the head and neck, but 
these are not the subject of this report.  The report d overall incidence varies between two and 
eight cases per million per year (1-4).  Approximately 10-35% of PPGLs have been reported to 
present as metastatic at the time of diagnosis and primary treatment; metastases typically develop 
after a median interval of approximately 5.5 years (5-7).  The most common sites of metastasis 
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location of metastatic lesions, with the worst progn sis reported for patients with liver and/or 
lung metastases (8).  Shorter survival has also recently been correlated with older age at the time 
of primary tumor, synchronous metastases, larger primary tumor size, and unresectable disease 
(5).  Once metastasis has occurred, treatment options are limited; there are currently no approved 
pharmacological treatments in the United States (US) for recurrent and/or metastatic (or 
previously referred to as malignant by WHO 2004 classification) PPGL.  Conventional, low-
specific-activity I-131 meta-iodobenzylguanidine (MIBG) therapy at high doses and cytotoxic 
chemotherapy with cyclophosphamide, vincristine, and dacarbazine (CVD) have been used in 
patients with recurrent and/or metastatic disease (9, 10).  Tyrosine kinase inhibitors such as 
sunitinib and stable and/or radiolabeled octreotide derivatives are also being explored (11-13). 
MIBG is a guanethidine derivative and is a substrate for the norepinephrine transporter 
(NET) present in the chromaffin cells of PPGLs.  MIBG has been labeled with radioactive 
isotopes of iodine for both diagnostic and therapeutic applications.  Conventional low-specific-
activity I-131 MIBG has been commercially available in the US and Europe for the imaging of 
neuroendocrine tumors, including PPGL, since the 1990s.  However, studies have reported that 
>99% of the MIBG molecules are not radiolabeled in commercial conventional preparations (14, 
15).  A major drawback of using high doses of conventional I-131 MIBG is the large amounts of 
unlabeled MIBG that compete for NET binding sites, lowering uptake of the therapeutically-
active I-131 labeled MIBG while also disrupting the norepinephrine (NE)-reuptake mechanism 
(15).  The resulting increase in circulating NE canlead to an elevated risk of significant 
cardiovascular side effects such as acute hypertensive crisis during or shortly after the infusion of 
conventional I-131 MIBG therapy (16, 17). 
To improve the benefit to risk profile of I-131 MIBG, a novel manufacturing process 
(Ultratrace®) has been developed to produce AZEDRA® (iobenguane I 131; Progenics 
Pharmaceuticals, Inc., New York, NY), a drug product with high-specific-activity and little to no 
unlabeled MIBG; thus potentially providing advantages over conventional I-131 MIBG in safety 
and efficacy for the treatment of patients with PPGL (18).  This open-label, multi-center, dose 
escalation phase 1 study was undertaken to determin the maximum-tolerated dose (MTD) of 
high-specific-activity I-131 MIBG in the treatment of metastatic and/or recurrent PPGL.  
Secondary measures included estimated radiation absorbed doses, objective radiographic tumor 
response by RECIST, biochemical response, survival, and safety and tolerability. 
Patients and Methods 
Patients 
The study protocol (NCT00458952) and all procedures w re approved by local Institutional 
Review Boards and the US Food and Drug Administration.  The study was conducted in 
accordance with the Declaration of Helsinki and the Int rnational Conference on Harmonisation 
Guidelines for Good Clinical Practice.  All subjects provided written informed consent before 
study entry.  To be eligible, patients 18 years of age or older had to have histologically 
confirmed evidence of PPGL with at least one measurable lesion on computed tomography (CT) 
or magnetic resonance imaging (MRI) that was also confirmed visible on diagnostic MIBG scan.  
Patients had disease that was metastatic or recurred following prior surgery.  Key exclusion 
criteria were radiographic evidence for active central nervous system lesions within 3 months of 
study entry, previous systemic radiotherapy within 6 months or chemotherapy within 30 days of 
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Study Design and Assessments 
This was a phase 1, open-label, single arm, multi-center, dose-finding study in patients with 
histologically confirmed PPGL that was metastatic and/or recurrent, regardless of disease 
progression status, designed to establish the MTD of high-specific-activity I-131 MIBG.  To 
determine the MTD, sequential dose escalation cohorts began with 3 patients at 222 MBq/kg (6 
mCi/kg), and proceeded according to a standard modified Fibonacci 3+3 trial design with dose 
increases at 37 MBq/kg (1 mCi/kg) increments, until the MTD was established (19).  To guard 
against inadvertently administering high levels of radioactivity, an upper limit for administered 
activity was based on a body weight of 75 kg.  Therefore, the first three dose levels were not to 
exceed 16.65, 19.43, or 22.2 GBq (450, 525, or 600 mCi).  The 222 MBq/kg (6 mCi/kg) starting 
dose was less than the calculated maximum administered activity resulting in 23 Gray (Gy) of 
absorbed dose to the kidneys according to a prior dosimetry study (20).  Toxicities were graded 
according to the US National Cancer Institute (NCI) ommon Terminology Criteria for Adverse 
Events (CTCAE version 3).  Potential DLTs consisted of CTCAE grade 4 hematologic toxicity 
>1 week duration; or the occurrence of any grade 3-4 non-hematologic toxicity. 
Key secondary objectives were to assess the radiation dose estimates, safety and tolerability, 
and preliminary efficacy of high-specific-activity I-131MIBG with regard to objective tumor 
response (OTR) by radiographic assessment, biochemial response, and survival.  Patients were 
evaluated at 3, 6, 9, and 12 months following treatment.  Safety was evaluated by collection of 
treatment emergent adverse events (AEs), ECGs, physical examination findings, vital sign 
measurements, and clinical laboratory data.  The biodistribution of I-131 MIBG was assessed by 
determination of total body residence time and by visual examination of whole body planar 
images.  Radiographic OTR was based on RECIST v1.0 and assessed by two blinded central 
independent reviewers and an adjudicator using CT or MRI scans of the chest, abdomen and 
pelvis performed at each assessment time point following investigational treatment.  For the 
assessment of biochemical response, serum chromogranin A (CgA) and 24-hour levels of urinary 
catecholamines/metanephrines were collected at baseline and every 3 months for one year post-
treatment.  Complete response (CR) was defined as a tumor marker value above the Upper Limit 
of Normal (ULN) at baseline and at or below the ULN at the assessed time point; partial 
response (PR) was defined as a value above ULN at baseline and decreased by at least 50% from 
the baseline value but still above the ULN.  Best overall tumor response by RECIST and best 
biochemical response were evaluated for treated patients during the 12-month efficacy period.   
After the first year, patients were followed every 6 months or until death (or withdrawal from the 
study) for overall survival (OS) and late radiation t xicity.  Late radiation toxicity was assessed 
using Radiation Therapy Oncology Group (RTOG)/European Organisation for Research and 
Treatment of Cancer (EORTC) Late Morbidity Scoring Scheme (21). 
Imaging 
For imaging, each patient received a single intravenous (IV) bolus of approximately 185 MBq (5 
mCi) high-specific-activity I-131 MIBG as the dosimetry (imaging) dose (20).  Following the 
dosimetry dose, serial anterior and posterior whole b dy images were taken 30-60 minutes post 
injection and prior to patient voiding, and again at two to four days and following patient 
voiding.  The geometric mean count of the first whole body studies represented 100% of 
administered activity.  An imaging standard was prepa d and placed in the field of view for all 
images and as a reference for correcting decay and c mera sensitivity changes.  Tumor uptake on 
the diagnostic MIBG scan was confirmed to correspond t  a designated target lesion seen on CT 
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scan, and the dosimetry dose showed typical biodistribution, the patient was administered a 
therapeutic dose 7 to 28 days following the dosimetry dose.  Data were evaluated to determine 
human radiation absorbed dose estimates to target lesions and normal organs in accordance with 
the Medical Internal Radiation Dose schema to account for patient-to-patient variation in 
radiation-absorbed doses to individual organs (22).  Absorbed radiation dose was calculated 
using OLINDA/EXM software (23). 
Study Drug Administration 
For the therapeutic dose administration of high-specific-activity I-131 MIBG, all patients were 
pre-treated with a saturated solution of potassium iodide for thyroid protection per standard 
practice.  The recommended infusion rate of IV administration of the therapeutic dose was 50 
mL over a period of 15 to 30 minutes.  Due to the theoretical risk for hypertensive crisis during 
and after therapeutic administration of I-131 MIBG, investigators had phentolamine available 
during each infusion.  ECGs and vital signs were obtained before and after each dose, Holter 
monitoring was initiated one hour pre-therapeutic dose and continued through approximately 23 
hours post-therapeutic dose.  A 12-lead ECG was performed upon the patient’s release from 
isolation and prior to discharge.  Any clinically significant ECG changes and findings were 
captured as reported AEs.  The radioactive drug product was handled only by trained personnel 
with proper shielding and monitoring following institu ional standard operating procedures 
and/or applicable guidance. 
Statistical Analyses 
The sample size was dictated by the ‘3+3’ study design.  Patients who received any dose of high-
specific-activity I-131 MIBG were included in the safety analysis.  The intent-to-treat (ITT) 
population was all patients who received a therapeutic dose; this was the primary analysis set for 
the determination of the MTD and efficacy measures.  Quantitative values were reported as 
means ± sd or median and range, as appropriate.  For categorical endpoints, Jonckheere-Terpstra 
test statistics were computed and P values presented (P < 0.05 was considered significant).  
Regression models for dose-response relationships were fit to the study data, and tests for the 
statistical significance of the association between dose level and response were conducted.  
Overall survival was defined as the time from the date of enrollment to the date of death from 
any cause or censored at the date the patient was last known to be alive.   All statistical analyses 
were performed using SAS Statistical Software (version 9.2; SAS Institute Inc., Cary, NC). 
Results 
Baseline Characteristics of Patients 
Of the 24 patients with metastatic and/or recurrent PPGL who consented for the trial, three 
patients did not meet all of the eligibility criteria at screening and did not receive study drug.  
The baseline characteristics of the 21 enrolled and dosed patients are presented in Table 1. 
Radiation Absorbed Doses 
The median dosimetry dose administered was 189 MBq (5.1 mCi), and the range was 181 to196 
MBq (4.9 to 5.3 mCi).  Target organ radiation dose e timates are presented in descending order 
of mean absorbed radiation dose in Table 2.  One patient was excluded from the dosimetry 
analyses because no imaging standard was used.  The highest estimated mean radiation absorbed 
dose estimates were observed in the thyroid and lower large intestinal wall (each 1.2 mGy/MBq).  
All other target organ mean radiation absorbed dose estimates were <1 mGy/MBq.  The total 
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respectively.  Even at the highest dose level in our st dy, the radiation dose levels did not exceed 
critical organ radiation dose limits used in external beam radiation therapy (EBRT) (24).  
Estimated tumor radiation absorbed dose varied from0.14 to 17 mGy/MBq with tumor volumes 
ranging from 5.9 cubic centimeters (cc) to 343 cc (mean, 79 cc). 
Maximum Tolerated Dose 
Due to the protocol-mandated dose ceilings for therap utic doses relative to body weight, 12 
(57%) of the 21 patients received doses lower than e planned levels on a per-body weight 
basis.  The weight limit rendered a body weight-based dose analysis not feasible as essentially all 
of the patients in the later dose levels were above the upper body weight limit of 75 kg.  The 
median therapeutic dose administered was 21.13 GBq (571 mCi), range 12 to 25.8 GBq (325-
696 mCi), which resulted in a median activity by actu l body weight of 240 MBq/kg (6.5 
mCi/kg), range 167-311 MBq/kg (4.5-8.4 mCi/kg).  To assess the results based on a fixed 
therapeutic dose in the study population, patients were grouped and analyzed by total 
administered activity, in two activity groups of ≤18.5 GBq (500 mCi) and >18.5 GBq. 
Four patients experienced DLTs, all of which were hematological events.  All of these 
patients received >18.5 GBq.  Figure 1 shows the administration of high-specific-activity I-
131MIBG at sequential dose-escalating levels and occurrence of DLTs in the treated patients.  
Actual administered activities for the four patients who experienced DLTs were betwe n 19.4 
GBq (524 mCi) and 25.2 GBq (680 mCi).  The DLTs were neutropenia (n=2), thrombocytopenia 
(n=1), and concurrent febrile neutropenia and thromb cytopenia (n=1).  All observed DLTs 
resolved within a month.  Based on the occurrence of DLTs in the planned 333 MBq/kg (9 
mCi/kg) cohort, the MTD was determined to be 296 MBq/kg (8 mCi/kg).  Six patients were 
treated in the MTD cohort. 
Safety 
The most frequently reported AEs were nausea (76%), fatigue (67%), dry mouth and vomiting 
(62% each), leukopenia, neutropenia, and thrombocytopenia (48% each), anemia, and salivary 
gland pain (43% each).  The majority (84%) of AEs were CTCAE grade 1-2 in severity.  Grade 3 
or 4 AEs were reported in 16 (76%) of the 21 patients, i cluding 5 (71%) of 7 patients who 
received ≤18.5 GBq and 11 (79%) of 14 patients who received >18.5 GBq (no statistically 
significant difference was observed between the dos groups).  Overall, the most common 
(≥10%) grade 3/4 events were neutropenia, leukopenia, thrombocytopenia, nausea, and vomiting; 
and most of these were considered related to study drug.  No patients were discontinued from the 
study due to AEs.  There were five deaths during the s udy that occurred from approximately 2.5 
months to up to 22 months after treatment, and all were assessed as unrelated to treatment.  The 
majority of serious AEs were also not considered related to study drug.  Hypertensive crises or 
cardiovascular risks were not observed in any patient.  There was no evidence of a dose effect on 
ECG changes or clinically significant vital sign changes.  Tachycardia was reported in four 
patients, and was not considered related to study drug.  During the long-term follow-up period of 
up to 3.5 years, most patients did not experience radiation toxicity as assessed by the 
RTOG/EORTC Late Morbidity Scoring Scheme.  The most clinically significant symptoms 
showing possible radiation toxicity was moderate bone pain/tenderness and/or moderate joint 
stiffness/pain reported by a total of 3 patients at 3-3.5 years post-treatment. 
Tumor Response 
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Overall, 14 (58%) patients completed the 12-month efficacy phase.  Table 3 presents the best 
confirmed overall objective tumor response (OTR) to treatment during the efficacy phase as 
assessed by RECIST for each dose group, and all patients.  The majority of patients had partial 
response (PR) or stable disease (SD) at 12 months.  No patient had a CR to treatment, but four 
patients, all of whom received >18.5 GBq of high-specific-activity I-131 MIBG, had a best 
confirmed overall OTR of PR.  The proportion of patien s with evaluable responses (n=19) who 
were successful (PR or CR) overall was 21% (95% CI:  0, 0.42).  However, the Jonckheere-
Terpstra test for dose response in the evaluable population indicated there was no trend in OTR 
by dose group at any time point. 
Biochemical tumor response 
Analyses of biochemical tumor response to treatment w re performed only on patients whose 
baseline blood and urine tumor markers were ≥ 1.5 x ULN.  For most serum and urine (24 hour) 
tumor markers, mean baseline and mean maximum change values differed due to high patient 
variability.  Jonckheere-Terpstra tests for dose-response at each time point indicated there were 
no trends by dose group for any of the tumor markers at any time point during the 12 months 
post-treatment (p>0.05).  Tumor markers norepinephrine, normetanephrine, epinephrine, 
metanephrine, dopamine, total metanephrines, chromogranin A (CgA) and vanillylmandelic acid 
were assessed.  Table 4 presents the overall best biochemical responses for serum CgA and total 
urine metanephrines observed during the 12-month period.  Based on the best biochemical 
response for serum CgA, 80% of patients with evaluable responses were successful overall (CR 
or PR).  Based on the best biochemical response for total metanephrines, 64% (95% CI:  0.36, 
0.93) of patients with evaluable responses were successful overall.   
Survival 
Survival time was calculated from the date of enrollment to the date of death from any cause or 
censored at the date the patient was last known to be alive.  Overall survival was 85.7% (18/21) 
at one year post-treatment and 61.9% (13/21) at two years post-treatment. 
Discussion and Conclusions 
The objectives of this phase 1 study were to determine the MTD of high-specific-activity carrier-
free I-131 MIBG for the treatment of metastatic and/or recurrent PPGL, evaluate the safety and 
tolerability, estimate radiation absorbed doses to target lesions and organs following dosimetry, 
and assess tumor response, biochemical response, and survival following treatment.   Overall, 
four patients experienced DLTs and all were hematological events.  Actual administered 
activities for these four patients were all >18.5 GBq (500 mCi).  Of these four patients, three 
patients with the highest activity levels demonstrated the best radiographic tumor response to 
treatment, with PR as the best overall response.  Tumor response for the other patient was not 
evaluated due to early discontinuation from the study.  Because two patients experienced dose-
limiting neutropenia in the 333 MBq/kg (9 mCi/kg) cohort, the MTD was determined to be 296 
MBq/kg (8 mCi/kg). 
Treatment success appeared to be related to total administered activity.  The majority of 
patients had PR or SD by radiographic tumor response at 12 months.  Four patients had best 
confirmed overall tumor response of PR, all of whom had received >18.5 GBq (500 mCi) of 
high-specific-activity I-131 MIBG.  Overall, best treatment responses were also observed at 
doses >18.5 GBq, and no patients who received ≤18.5 GBq achieved PR by RECIST.  For most 
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variability and small sample size.  There were no dose-relationship trends for any of the tumor 
markers.  Since hypertension is one of the symptoms in patients who have primarily 
norepinephrine secreting tumors, the use of antihypertensive medications was also analyzed as 
an exploratory endpoint evaluating clinical benefit in 15 patients who had documented use of 
baseline antihypertensive medications.  Of these pati nts, five (33.3%) had either a decrease or 
discontinuation in the medications within 12 months of tudy drug treatment. 
The majority of AEs in the phase 1 study were grade 1-2 in severity.  Grade 3-4 AEs were 
consistent with the anticipated toxicities following radiotherapy and the expected pattern of AEs 
described in I-131 MIBG therapeutic studies (18, 23). 
Limitations of this study are related to the small size of this trial, particularly with respect to 
interpretation of efficacy which is also impacted by the differences in therapeutic dose levels.  
Nonetheless, the preliminary safety and efficacy data from this phase 1 study support the clinical 
development of high-specific-activity I-131 MIBG in patients with metastatic and/or recurrent 
PPGL.  Based on the MTD of 296 MBq/kg (8 mCi/kg) determined from this study, a target 
therapeutic administered activity of 18.5 GBq (500 mCi) was selected in the open-label, 
multicenter phase 2b study, which is currently ongoi  in the long-term follow-up phase 
(NCT00874614).   
There are no other comparative studies for any systemic therapeutic options in this ultra-rare 
disease.  Only one phase 2 clinical trial with high dose conventional I-131 MIBG has been 
published, and no phase 3 clinical trials exist (25).  Van Hulsteijn et al conducted a meta-analysis 
of radiographic and biochemical tumor response on 17 I-131 MIBG studies in a total of 243 
patients with metastatic and/or recurrent PPGL (10).  Response rates showed high variability; 
and treatment regimens, administered doses, and duration of follow-up also differed widely 
across studies.  Individual tumor dosimetry was not rou inely performed to optimize dose 
delivery, and version(s) of RECIST criteria was only used in four studies to assess objective 
tumor response. The analysis suggests that most patients experienced either PR (27% 
[radiographic], 40% [biochemical]) or SD (52% [radiographic], 21% [biochemical]) responses 
(mostly not by RECIST).  An older meta-analysis by Loh et al reported similar radiographic 
response rates of 26% PR and 57% SD; while 13% of patients experienced PD (17).  The large 
proportion of patients with SD is also observed in untreated patients with metastatic and/or 
recurrent PPGL, owing to perhaps the indolent nature of the disease (26).  A single-arm phase 2 
investigator-initiated study with sunitinib in locally advanced or metastatic PPGL has been 
published with interim results up to 12 weeks.  The study reported that of 14 patients with 
evaluable radiological response, 3 patients (21.4%) had PR at 12 weeks with one unconfirmed 
response (27).  Thus, based on the reported safety and tolerability, and efficacy of radiological 
response at 12 months, high-specific-activity I-131 MIBG may be an effective therapeutic option 
for patients with iobenguane-avid, metastatic and/or recurrent PPGL for whom there are no 
approved therapies. 
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Figure 1.   Administration of high-specific-activity I-131 MIBG at sequential escalating 
dose levels and occurrence of dose-limiting toxicities (DLTs) in 21 treated patients. 
AZEDRA® and Ultratrace® are registered trademarks of Progenics Pharmaceuticals, Inc. 
Table 1: Baseline characteristics of 21 treated patients 
Characteristics Value 
Age (years)  
Median 49 
Range 30-72 
Male, n (%) 13 (61.9) 
Race, n (%)  
White/Caucasian 16 (76.2) 
Black  3 (14.3) 
Asian 2 (9.5) 
Height (cm)  
Median 172.7 
Range  145-201 
Weight (kg)  
Median 80.7 
Range 42-126 
Primary Diagnosis, n (%)  
Pheochromocytoma 10 (47.6) 
Paraganglioma 11 (52.4) 
Prior Anti-cancer Therapies for PPGL, n (%)  
   Radiation therapy1  12 (57.1) 
   Chemotherapy (e.g., CVD and others) 6 (28.6)  
   Octreotide  3 (14.3)  
1.  Includes external beam radiation therapy and coventional I-131 MIBG 
Table 2: Radiation absorbed dose estimates by target o an following dosimetry doses of 
high-specific-activity I-131 MIBG in 20 dosimetry-evaluable patients 
Target Organ Mean (mGy/MBq) Minimum (mGy/MBq) Maximum (mGy/MBq) 
Thyroid  1.2 0.44 2.0 
Lower large intestine wall  1.2 0.74 1.7 
Salivary glands  0.87 0.28 1.9 
Urinary bladder wall  0.67 0.62 0.71 
Upper large intestine wall  0.51 0.34 0.71 
Liver  0.48 0.16 2.7 
Spleen  0.47 0.23 0.99 
Kidneys  0.42 0.14 0.73 
Heart wall  0.35 0.20 0.48 
Lungs  0.32 0.13 0.63 
Small intestine  0.19 0.14 0.26 
Osteogenic cells   0.14 0.070 0.26 
Gallbladder wall  0.13 0.065 0.36 
Ovaries  0.13 0.094 0.20 
Uterus  0.12 0.082 0.18 
Pancreas  0.11 0.053 0.20 
Adrenals  0.11 0.049 0.22 
Total body  0.10 0.053 0.17 
Stomach wall  0.094 0.050 0.16 
Thymus  0.078 0.038 0.14 
Muscle  0.077 0.041 0.13 
Red marrow  0.074 0.041 0.13 
Testes  0.072 0.042 0.13 
Breasts  0.065 0.031 0.12 
Skin  0.058 0.030 0.11 
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Table 3: Best overall objective tumor response as assessed by RECIST, categorized by 
total administered activity of high-specific-activiy I-131 MIBG  
Overall Response by RECIST 
Total Administered Activity Overall (N=21) n (%) 
≤18.5 GBq (N=7) n (%) >18.5 GBq (N=14) n (%) 
Complete Response  0 0 0 
Partial Response   0 4 (28.6) 4 (19.0) 
Stable Disease  6 (85.7) 7 (50.0) 13 (61.9) 
Progressive Disease 0 2 (14.3) 2 (9.5) 
Not Evaluable  1a (14.3) 1b (7.1) 2 (9.5) 
a Not evaluated because patient died of hepatic failure prior to any efficacy assessments. 
b Not evaluated because patient was discontinued from the study for starting alternate chemotherapy. 
Table 4: Best biochemical tumor response during 12 months post-treatment, categorized by 
total administered activity of I-131 MIBG and overall 
 Total Administered Activity  
Biochemical Tumor Response,            Best Overall ≤18.5 GBq (N=7) n (%) >18.5 GBq (N=14) n (%) Total (N=21) n (%) 
Serum chromogranin A    
Complete Response (CR) 3 (42.9) 4 (28.6) 7 (33.3) 
Partial Response (PR) 1 (14.3) 4 (28.6) 5 (23.8) 
Stable Disease (SD) 0 3 (21.4) 3 (14.3) 
Progressive Disease (PD) 0 0 0 
Normal at Baseline (NNPD) 2 (28.6) 3 (21.4) 5 (23.8) 
Not Evaluable (NE) 1 (14.3) 0 1 (4.8) 
Proportion (of ITT) with Overall Response of CR or PR (95% CI) 0.75 (0.51, 0.99) 
Proportion (of Evaluable) with Overall Response of CR or PR (95% CI) a 0.80 (0.56, 1.04) 
Jonckheere-Terpstra test for dose response a,b 0.284 
Total Metanephrines 24 hour    
Complete Response (CR) 2 (28.6) 3 (21.4) 5 (23.8) 
Partial Response (PR) 0 4 (28.6) 4 (19.0) 
Stable Disease (SD) 2 (28.6) 3 (21.4) 5 (23.8) 
Progressive Disease (PD) 0 0 0 
Normal at Baseline (NNPD) 1 (14.3) 1 (7.1) 2 (9.5) 
Not Evaluable (NE) 2 (28.6) 3 (21.4) 5 (23.8) 
Proportion (of ITT) with Overall Response of CR or PR (95% CI) 0.47 (0.22, 0.72) 
Proportion (of Evaluable) with Overall Response of CR or PR (95% CI) a 0.64 (0.36, 0.93) 
Jonckheere-Terpstra test for dose response a,b 1.000 
a Excludes non-evaluable responses. 
b p-value is exact and 2-sided. 
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